Shots:
- Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer
- Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus mid-single to low double-digit royalties for both therapeutic and diagnostic agents of OncoACP3
- The transaction is subject to regulatory approvals and customary closing conditions, with expected completion in the 3Q’25. Ongoing IND-enabling activities aim to support the application for a P-I therapeutic study using 225Ac-OncoACP3
Ref: Globenewswire | Image: Globenewswire| Press Release
Related News:- Aytu BioPharma Collaborates with Fabre-Kramer Pharmaceuticals to Commercialize Exxua (Gepirone) in the US for Major Depressive Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
